European Commission Revoked Approval for Cancer Drug Aumseqa
The decision followed a legal challenge by AstraZeneca regarding data protection rule violations.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Should pharmaceutical companies be permitted to use rival clinical data to gain drug approval?
The European Commission has revoked the EU marketing authorization for the cancer drug Aumseqa. This action followed a finding that the drug's 2022 approval application improperly utilized protected clinical data from AstraZeneca's Tagrisso.
Why it matters
The revocation highlights the strict enforcement of EU data exclusivity rules, which protect pharmaceutical innovators from having their clinical trial results referenced by competitors during set timeframes.
Tagrisso has held EU data protection since February 4, 2016, and generated $3.8 billion in sales during the first half of 2026. The standard duration for EU drug data protection is 8 years.
The players
European Commission
This is the executive branch of the European Union responsible for proposing legislation, implementing decisions, and upholding the union's treaties.
AstraZeneca
This is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines.
European Medicines Agency
This is an agency of the European Union in charge of the evaluation and supervision of medicinal products for use in the EU.
Hansoh
This is a Chinese pharmaceutical company that develops and markets medicines in therapeutic areas including oncology and metabolic diseases.
SFL Pharma
This is a regulatory and scientific consultancy firm that manages pharmaceutical product applications and compliance requirements.
The details
The EMA determined that the Aumseqa application submitted by SFL Pharma in 2022 relied on trial data from AstraZeneca's FLAURA study, which was still protected. Following a lawsuit filed by AstraZeneca before the General Court of the EU, the commission moved to strip the drug of its authorization.
Timeline
February 4, 2016: Tagrisso EU data protection period began.
2022: SFL Pharma submitted the Aumseqa application.
November 2025: EMA recommended approval for Aumseqa.
February 2026: Aumseqa received initial EU approval.
September 25, 2026: EC signed a letter revoking the Aumseqa authorization.
Health Landscape
This revocation reflects a broader trend of rigorous oversight regarding the EU pharmaceutical data protection regulatory framework. It underscores the high stakes for manufacturers who attempt to leverage clinical trials from legacy blockbuster drugs during exclusivity windows.
Patients currently prescribed Aumseqa may face disruptions in supply or transition to alternative treatments due to the revocation. Health providers will need to consult the latest EMA guidance to adjust patient care plans accordingly.
The takeaway
Pharmaceutical companies must ensure their applications strictly respect existing exclusivity periods to avoid costly regulatory reversals. Innovators are increasingly proactive in defending their proprietary clinical trial data through legal channels.
Further reading
For more information on the evolving regulatory environment for oncology treatments, visit our Cancer section.
Source note: This article includes information reported by FiercePharma.
Live Poll
Should pharmaceutical companies be permitted to use rival clinical data to gain drug approval?
